AMG 102 Plus ECX for Unresectable Locally Advanced or Metastatic Gastric or Esophagogastric Junction Cancer

NCT00719550 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

130

Enrollment

INDUSTRY

Sponsor class

Conditions

Esophagogastric Junction Adenocarcinoma
Gastric Cancer
Esophageal Cancer

Interventions

DRUG: Capecitabine
DRUG: Epirubicin
DRUG: AMG 102
DRUG: Cisplatin
DRUG: Placebo

Sponsor

Amgen